Abstract
The hallmark of neurofibromatosis type 1 (NF1) are multiple dermal neurofibromas. They show high inter- and intrafamilial variability for which the influence of modifying genes is discussed. NF1 patients presenting microdeletions spanning NF1 and several contiguous genes have an earlier onset and higher number of dermal neurofibromas than classical NF1 patients, pointing to one of the deleted genes as modifier. Expression analysis of 13 genes of the microdeletion region in dermal neurofibromas and other tissues revealed four candidates for the modification of neurofibroma formation: CENTA2, RAB11FIP4, C17orf79, and UTP6.
Avoid common mistakes on your manuscript.
Introduction
Neurofibromatosis type 1 (NF1) [MIM16220] is an autosomal dominant tumor predilection syndrome caused by mutations in the NF1 gene on chromosome 17q11.2 [1]. Its hallmark symptom is multiple benign dermal neurofibromas. The observed inter- and intrafamilial variability of several NF1 symptoms (e.g., neurofibroma number) has led to the hypothesis that they are modified by other genes [2]. Among the proposed candidates are genes influencing somatic mutation rates [3], genes involved in pathways regulated by neurofibromin, as well as steroid hormones and their receptors [4]. The rare ‘NF1 microdeletion syndrome’ is of special interest in the search for modifying genes. These patients carry a heterozygous microdeletion of NF1 and several contiguous genes [5–8] and often have a severe clinical phenotype including mental retardation, congenital heart defects, and an excessive number and early onset of dermal neurofibromas [9]. Fourteen protein-coding and two microRNA genes lie within the most prevalent 1.5 Mb deletion [10–13], which arises from unequal meiotic crossover of two highly homologous low copy repeats flanking NF1 [14]. It seems likely that the haploinsufficiency of one or more of these genes contributes to the severe phenotype. Candidate genes for mental retardation, congenital heart malformation, and overgrowth have been identified among them [15–17]. None has as yet been associated with dermal neurofibroma formation, thought to be triggered by second hit NF1 mutations in Schwann cells or their precursors [18] with the subsequent involvement of mast cells and fibroblasts [19, 20]. We hypothesize that interindividual variations in one of the genes of the microdeletion region also account for the variable neurofibroma number in classical NF1 patients. If so, this gene should be expressed in at least one type of neurofibroma precursor cell and presumably also in the neurofibroma itself. We therefore examined the expression of 13 of the 14 protein-coding genes in neurofibromas, peripheral nerve tissue, and cell types involved in neurofibroma formation. The SUZ12 pseudogene SUZ12P was excluded because of its extremely high homology to sequences on chromosome 19. The location and orientation of these genes together with the low copy repeats are depicted in Fig. 1.
Materials and methods
Tissues and cells
Nine dermal neurofibromas from seven unrelated NF1 patients and plexiform neurofibroma tissue from four unrelated patients were received. Macroscopically normal peripheral nerve adhering to tumor was obtained in two cases. Two peripheral nerve samples (N. femoralis and N. ulnaris) were received from one NF1 patient. Samples were surgically excised and directly transferred to RNAlater™ (Ambion). Tissue of malignant nerve sheath tumors (MPNST) was obtained from two unrelated NF1 patients and flash frozen in liquid nitrogen. All patients gave informed consent. Primary human fibroblasts derived from the skin of NF1 patients and a healthy control and the NF1-MPNST cell line NFS-1 (kindly provided by Dr. Vincent Riccardi) were cultured in DMEM with 10% FCS. NFS-1, suggested to be of Schwann cell origin [18], shows 26% of the neurofibromin amount of control fibroblasts (J. Griesser, doctoral thesis), indicating an unstable protein. The human mast cell line LAD2 (kindly provided by Dr. Kirshenbaum, NIH, NIAID) was cultured as described [21].
LOH analysis
Two dermal neurofibromas from 4 NF1 patients were subjected to loss of heterozygosity (LOH) analysis as described [22, 23] with markers D17S907 (located within the schlafen family member 12-like gene (SLFN12L), 4.16 Mb downstream from NF1) and either IVs27TG24.8, D17S1800, or IVs27ac28.4 (located within NF1) (kindly provided by Dr. Kehrer-Sawatzki).
Expression analysis
Total RNA was isolated using the RNeasy or the RNeasy Fibrous Tissue Mini Kit (Qiagen) according to the manufacturer’s protocol and treated with DNase I Amplification Grade (Invitrogen Life Technologies). One microgram thereof was reverse transcribed with the SuperScript™ First-Strand Synthesis system and random hexamers (Invitrogen Life Technologies). cDNA quality was controlled by amplifying part of the housekeeping gene RPII [24]. PCR conditions using 3 μl cDNA as template were 95°C for 2 min, followed by 35–40 cycles of 30 s at 95°C, 30 s at annealing temperature, 30 s at 72°C, followed by 5 min at 72°C. PCR products were separated on 1.5% agarose gels stained with ethidium bromide. Band intensity was measured with Kodak 1D Image Analysis Software and genes displaying less than 10% of the expression measured for the housekeeping gene were defined as not expressed.
The expression of CENTA2, RAB11FIP4, C17orf79, and UTP6 was also measured in a LightCycler 1.0 (Roche Applied Science) with the QuantiTect SYBR Green PCR mix (Qiagen) and 2 μl of diluted cDNA according to the manufacturer’s protocol. For analysis, the crossing point (C t) values were determined with the Fit Points method of the Lightcycler 3.5 software and a fluorescence threshold (F t) of 0.01. The initial template fluorescence (F 0) was calculated as described [25]. Normalization was carried out with the geometric mean of the reference genes G6PDH and TBP [24]. Primers, annealing temperatures, and product sizes are listed in Table 1.
Results
LOH analysis
A constitutive NF1 microdeletion could be excluded for the four NF1 patients tested (NF.326, NF.328, NF.329, and NF.331) as at least one of the two neurofibromas tested showed both NF1 copies. One neurofibroma of patient NF.326 showed a somatic deletion at both markers (peak reduction by approximately 44%) and was subjected to separate real-time expression analysis together with one NF.326 tumor without LOH. In the remaining three patients, investigation of transcribed polymorphic sites in genes lying within the deletion interval was not informative.
Expression analysis
Four of 13 genes (CENTA2, RAB11FIP4, C17orf79, and UTP6) were found to be expressed in all dermal neurofibromas (Table 2), all plexiform neurofibromas, peripheral nerve tissue (Table 3), and most cultured cells (Table 4). In all plexiform neurofibromas and most nerve tissue samples, six more genes (ATAD5, C17orf42, RNF135, EVI2B, SUZ12, and LRRC37B) were expressed. One gene, OMG, was not expressed in any sample. CENTA2, RAB11FIP4, C17orf79, and UTP6 were investigated in detail as candidate modifiers.
Real-time RT-PCR of candidate genes
Real-time RT-PCR of the candidate genes shows an upregulation of CENTA2 (significant; Mann–Whitney test, p-value 0.04), RAB11FIP4 (p-value 0.046), and UTP6 in dermal neurofibromas compared to peripheral nerve tissue (Table 5). No distinct change in regulation was found for C17orf79 where two samples showed a reduction, four samples were unchanged, and one showed an increase in expression.
Direct comparison of one neurofibroma from NF.326 with LOH (comprising at least NF1 to SLFN12L and thus including RAB11FIP4, C17orf79, and UTP6) to one of the same patient without LOH revealed a reduced upregulation of RAB11FIP4 (310% to 113%) and a greater downregulation of UTP6 (45% to 12%) in the tumor with LOH. CENTA2 and C17orf79 showed no difference between the two samples (Fig. 2).
In contrast to the dermal neurofibromas, C17orf79 was upregulated in plexiform neurofibromas and even more so in MPNSTs (Table 5). Great discrepancies were found in some cases between the data from cultured cells and the data from tissue (Table 5). A reduced expression, interesting in view of our hypothesis, was found for RAB11FIP4 in fibroblasts and UTP6 in LAD2 cells.
Discussion
We hypothesize that one of the genes lying in the NF1 microdeletion region not only causes the high number and early onset of neurofibromas in the microdeletion patients but also accounts for the variation of neurofibroma number seen in classical NF1 patients. Accordingly, they would differ in level or activity of the putative modifying protein in cell types involved in neurofibroma formation. As only a difference in an expressed gene can have a modifying effect, we examined the expression of 13 genes of the NF1 microdeletion region in peripheral nerve tissue, dermal, and plexiform neurofibromas. The majority of cells in a neurofibroma are Schwann cells, with an unknown percentage of NF1 −/− Schwann cells. The other cell types are underrepresented which is why we also examined representative cell cultures such as primary fibroblasts, a mast cell line and, as representative for Schwann cells, an MPNST cell line.
Only four genes, CENTA2, RAB11FIP4, C17orf79, and UTP6, showed expression in all of the dermal and plexiform neurofibromas investigated as well as in nerve tissue, primary fibroblasts, and the MPNST cell line. They seem to function in basic cellular processes the disruption of which may promote aberrant growth. CENTA2 is a GTPase activating protein (GAP) for ARF6 [26], an ADP-ribosylation factor known to regulate tumor cell invasion [27]. The neurally expressed RAB11FIP4 is involved in the control of membrane trafficking during cytokinesis [28]. UTP6 influences apoptosome-mediated apoptosis via interaction with Apaf-1 [29]. C17orf79 (COPR5) binds arginine methyltransferase 5 (PRMT5) and thereby acts on the promoters of cyclin E1 (CCNE1) and the tumor suppressor gene NM23. COPR5 overexpression leads to reduced CCNE1 levels [30].
Real-time RT-PCR investigation of the candidate gene expression level revealed no clear downregulation in neurofibroma tissue compared to peripheral nerve. Two explanations for these findings are conceivable. First, it is possible that downregulation of a modifying gene occurs only during neurofibroma initiation and it is upregulated thereafter. Second, the level might only be reduced in one neurofibroma cell type but increased in others. Therefore, it seemed reasonable to also investigate the different cell types a dermal neurofibroma is comprised of. However, because of the sometimes strong discrepancies between the in vivo and in vitro data, these results have to be interpreted with caution. RAB11FIP4 was found to be reduced in NF1 +/− fibroblasts, UTP6 in the mast cell line. Increased expression of both genes was measured in the other cell types. This would support our second explanation mentioned above.
Direct comparison of a neurofibroma with LOH to one without LOH from the same patient showed the expected reduction in the neurofibroma with LOH only in the case of RAB11FIP4 and UTP6. Interestingly, CENTA2 and C17orf79 expression did not differ between both tumors. The LOH tumor carries an atypical deletion comprising at least NF1 to SLFN12L. As CENTA2 is located upstream of NF1, it might not be deleted, which would explain the unchanged expression. C17orf79, however, is located within the deleted region. In this case, upregulation of the remaining allele in the tumor with LOH is one possible explanation. Another possibility is higher expression of C17orf79 in one tumor cell type which has a growth advantage in the LOH tumor. Together with the finding of C17orf79 overexpression in plexiform neurofibroma and MPNST tissue, this points to an interesting function of this gene in tumor tissue.
In summary, CENTA2, RAB11FIP4, C17orf79, and UTP6 are candidates for modifying NF1 neurofibroma formation. Further studies, especially on protein activity in different NF1 patients, are necessary to elucidate their specific role in neurofibroma formation.
References
Rasmussen SA, Friedman JM (2000) NF1 gene and neurofibromatosis 1. Am J Epidemiol 151:33–40
Easton DF, Ponder MA, Huson SM, Ponder BA (1993) An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 53:305–313
Wiest V, Eisenbarth I, Schmegner C, Krone W, Assum G (2003) Somatic NF1 mutation spectra in a family with neurofibromatosis type 1: toward a theory of genetic modifiers. Hum Mutat 22:423–427 doi:10.1002/humu.10272
Fishbein L, Zhang X, Fisher LB, Li H, Campbell-Thompson M, Yachnis A et al (2007) In vitro studies of steroid hormones in neurofibromatosis 1 tumors and Schwann cells. Mol Carcinog 46:512–523 doi:10.1002/mc.20236
Clementi M, Boni S, Mammi I, Favarato M, Tenconi R (1996) Clinical application of genetic polymorphism in neurofibromatosis type 1. Ann Genet 39:92–96
Cnossen MH, van der Est MN, Breuning MH, van Asperen CJ, Breslau-Siderius EJ, van der Ploeg AT et al (1997) Deletions spanning the neurofibromatosis type 1 gene: implications for genotype–phenotype correlations in neurofibromatosis type 1. Hum Mutat 9:458–464 doi:10.1002/(SICI)1098-1004(1997)9:5<458::AID-HUMU13>3.0.CO;2-1
Rasmussen SA, Colman SD, Ho VT, Abernathy CR, Arn PH, Weiss L et al (1998) Constitutional and mosaic large NF1 gene deletions in neurofibromatosis type 1. J Med Genet 35:468–471
Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-Sawatzki H et al (2004) Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 23:111–116 doi:10.1002/humu.10299
Mensink KA, Ketterling RP, Flynn HC, Knudson RA, Lindor NM, Heese BA et al (2006) Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the literature. J Med Genet 43:e8 doi:10.1136/jmg.2005.034256
Jenne DE, Tinschert S, Dorschner MO, Hameister H, Stephens K, Kehrer-Sawatzki H (2003) Complete physical map and gene content of the human NF1 tumor suppressor region in human and mouse. Genes Chromosomes Cancer 37:111–120 doi:10.1002/gcc.10206
De Raedt T, Brems H, Lopez-Correa C, Vermeesch JR, Marynen P, Legius E (2004) Genomic organization and evolution of the NF1 microdeletion region. Genomics 84:346–360 doi:10.1016/j.ygeno.2004.03.006
Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T (2003) New microRNAs from mouse and human. RNA 9:175–179 doi:10.1261/rna.2146903
Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O et al (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37:766–770 doi:10.1038/ng1590
Lopez CC, Brems H, Lazaro C, Marynen P, Legius E (2000) Unequal meiotic crossover: a frequent cause of NF1 microdeletions. Am J Hum Genet 66:1969–1974 doi:10.1086/302920
Venturin M, Guarnieri P, Natacci F, Stabile M, Tenconi R, Clementi M et al (2004) Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Med Genet 41:35–41 doi:10.1136/jmg.2003.014761
Venturin M, Bentivegna A, Moroni R, Larizza L, Riva P (2005) Evidence by expression analysis of candidate genes for congenital heart defects in the NF1 microdeletion interval. Ann Hum Genet 69:508–516 doi:10.1111/j.1529-8817.2005.00203.x
Douglas J, Cilliers D, Coleman K, Tatton-Brown K, Barker K, Bernhard B et al (2007) Mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth. Nat Genet 39:963–965 doi:10.1038/ng2083
Riccardi VM (2007) The genetic predisposition to and histogenesis of neurofibromas and neurofibrosarcoma in neurofibromatosis type 1. Neurosurg Focus 22:E3 doi:10.3171/foc.2007.22.6.4
Yang FC, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR et al (2003) Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/− mast cells. J Clin Invest 112:1851–1861 doi:10.1172/JCI200319195
Yang FC, Chen S, Clegg T, Li X, Morgan T, Estwick SA et al (2006) Nf1+/− mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Hum Mol Genet 15:2421–2437 doi:10.1093/hmg/ddl165
Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA et al (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 27:677–682 doi:10.1016/S0145-2126(02)00343-0
Kluwe L, Friedrich RE, Mautner VF (1999) Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. Cancer Genet Cytogenet 113:65–69 doi:10.1016/S0165-4608(99)00006-0
Kehrer-Sawatzki H, Tinschert S, Jenne DE (2003) Heterogeneity of breakpoints in non-LCR-mediated large constitutional deletions of the 17q11.2 NF1 tumour suppressor region. J Med Genet 40:e116 doi:10.1136/jmg.40.10.e116
Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A (2004) Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 313:856–862 doi:10.1016/j.bbrc.2003.11.177
Rutledge RG, Cote C (2003) Mathematics of quantitative kinetic PCR and the application of standard curves. Nucleic Acids Res 31:e93 doi:10.1093/nar/gng093
Venkateswarlu K, Brandom KG, Yun H (2007) PI-3-kinase-dependent membrane recruitment of centaurin-alpha2 is essential for its effect on ARF6-mediated actin cytoskeleton reorganisation. J Cell Sci 120:792–801 doi:10.1242/jcs.03373
Tague SE, Muralidharan V, D'Souza-Schorey C (2004) ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci U S A 101:9671–9676 doi:10.1073/pnas.0403531101
Fielding AB, Schonteich E, Matheson J, Wilson G, Yu X, Hickson GR et al (2005) Rab11-FIP3 and FIP4 interact with Arf6 and the exocyst to control membrane traffic in cytokinesis. EMBO J 24:3389–3399 doi:10.1038/sj.emboj.7600803
Piddubnyak V, Rigou P, Michel L, Rain JC, Geneste O, Wolkenstein P et al (2007) Positive regulation of apoptosis by HCA66, a new Apaf-1 interacting protein, and its putative role in the physiopathology of NF1 microdeletion syndrome patients. Cell Death Differ 14:1222–1233 doi:10.1038/sj.cdd.4402122
Lacroix M, Messaoudi SE, Rodier G, Le Cam A, Sardet C, Fabbrizio E (2008) The histone-binding protein COPR5 is required for nuclear functions of the protein arginine methyltransferase PRMT5. EMBO Rep 9:452–458 doi:10.1038/embor.2008.45
Acknowledgements
We would like to thank Drs. Berlien, Hamideh, Müller, Riedel (Dept. of Lasermedicine, Elisabeth-Klinik, Berlin), Kunzi-Rapp (ILM, Ulm), Baezner, Hein (Dept. of Neurosurgery, University Hospital Ulm), and Tinschert (Institute for Clinical Genetics, Technical University Dresden) for supplying tissue samples and H. Goetz, A. Siegel, A. Schwandt, and H. Spoeri of our institute for the expert technical assistance. This work was supported by grant no. KA 898/6-1 from DFG. The authors declare that the experiments of this work comply with the current German laws.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bartelt-Kirbach, B., Wuepping, M., Dodrimont-Lattke, M. et al. Expression analysis of genes lying in the NF1 microdeletion interval points to four candidate modifiers for neurofibroma formation. Neurogenetics 10, 79–85 (2009). https://doi.org/10.1007/s10048-008-0154-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10048-008-0154-0